AMPLIFY™ Technology Enhances Prenatal Screening for 22q11.2 Microdeletion
Myriad Genetics
APRIL 15, 2024
4 In a recent presentation, Dale Muzzey, PhD, Chief Scientific Officer at Myriad, summarized the findings this way: “We followed up with providers regarding their patients who screened positive for 22q. 5 Clear Benefits for Healthcare Providers and Patients The benefits to a high PPV are, well, myriad. Mayo Clinic.
52 
Let's personalize your content